Free Trial
NASDAQ:NOVT

Novanta Q3 2026 Earnings Date & Estimates

Novanta logo
$140.07 -5.48 (-3.77%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$139.77 -0.30 (-0.21%)
As of 04:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novanta is scheduled to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. The conference call is scheduled for November 10, 2026 at 8:00 AM ET.

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call Date
Conference Call
8:00 AM ET

What Analysts Expect from Novanta in Q3 2026

Novanta is expected to post earnings of $0.9670 per share on revenue of $301.02 million. In the same quarter a year earlier Novanta reported $0.87 per share on revenue of $247.84 million. Novanta last reported on August 5, 2026, posting $0.89 per share and beating the $0.83 consensus estimate. Novanta has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.9670
Expected Revenue
$301.02 million
Prior-Year EPS
$0.87
Prior-Year Revenue
$247.84 million
Expected EPS Growth
+11.1%
Expected Revenue Growth
+21.5%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.89 (Beat by +$0.06)
Last Quarter Revenue
$265.81 million
EPS Beat Rate
7 of last 8 quarters

Novanta Q3 2026 Earnings FAQ

Novanta (NASDAQ:NOVT) has confirmed it will report Q3 2026 earnings on Monday, November 9, 2026, after market closes.

Novanta's Q3 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Novanta to post earnings of $0.9670 per share for Q3 2026.

The consensus revenue estimate for Novanta is $301.02 million for Q3 2026.

Novanta Earnings Headlines

Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
Novanta (NASDAQ:NOVT) Stock Rating Cut to "Hold" at Zacks Research
Fabrinet (NYSE:FN) and Novanta (NASDAQ:NOVT) Critical Review
See More Novanta Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Novanta? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novanta and other key companies, straight to your email.

About Novanta

Novanta (NASDAQ:NOVT) (NASDAQ:NOVT) is a medical technology and advanced equipment company that develops components and subsystems used by original equipment manufacturers. Its technologies are designed for applications requiring precision motion, photonics, imaging, and other specialized capabilities, with a primary focus on healthcare and medical device markets.

The company’s offerings include precision motion control systems, motors, pumps, encoders, laser sources, optical components, and beam-delivery systems. Novanta also provides medical technologies such as surgical visualization and imaging systems, insufflation equipment, fluid-management products, and other components used in minimally invasive and robotic-assisted procedures.

Novanta serves medical device and industrial customers internationally, with operations and customer relationships spanning North America, Europe, and Asia. The company traces its history to businesses established in the late 1960s and adopted the Novanta name in 2016 after operating as GSI Group. Novanta is led by Chief Executive Officer Matthijs Glastra.

View Novanta Profile